You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 9, 2025

Claims for Patent: 5,733,919

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,733,919

Title:	Compositions for inhibiting platelet aggregation
Abstract:	The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## as 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.
Inventor(s):	Gelotte; Karl M. (North Wales, PA)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	08/735,878
Patent Claims:	1. A pharmaceutical composition comprising a) a pharmaceutically effective amount of a compound having the formula ##STR8## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.1-10 arylalkyl; R.sup.5 is ##STR9## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy; p is zero or one; and m is an integer from two to six; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) between about 50-500 milliosmoles of a tonicity adjusting agent. 2. A composition comprising about 0.01-0.5 mg/ml of a compound having the formula ##STR10## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.1-10 arylalkyl; R.sup.5 is ##STR11## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy; p is zero or one; and m is an integer from two to six; about 2-100 mM citrate buffer, between about 50-500 milliosmoles tonicity adjusting agent, and water. 3. A composition of claim 2 comprising about 0.01-0.5 mg/ml of a compound having the formula ##STR12## and the pharmaceutically acceptable salts thereof, wherein R.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.1-10 arylalkyl; R.sup.5 is ##STR13## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy; p is zero or one; and m is an integer from two to six; about 2-20 mM citrate buffer, about 290 milliosmoles tonicity adjusting agent, and water. 4. A pharmaceutical composition of claim 3, wherein the amount of 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid is about 0.05 to about 0.25 mg/ml, and the amount of citrate buffer is about 2-20 mM. 5. A pharmaceutical composition of claim 4, wherein the amount of 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid is about 0.25 mg/ml, the amount of citrate buffer is about 10 mM, the amount of tonicity adjusting agent is about 290 milliosmoles, and the pH is about 6.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.